20.09.2024 14:24 | NFX | £300,000 Fundraise | RNS |
18.06.2024 18:37 | NFX | IN BRIEF: Nuformix shares fall despite interim loss narrowing | Alliance |
18.06.2024 07:00 | NFX | Half-year Report | RNS |
17.06.2024 10:37 | NFX | Nuformix touts patent wins for idiopathic pulmonary fibrosis treatment | Alliance |
17.06.2024 07:00 | NFX | Patent Update | RNS |
19.03.2024 14:39 | NFX | Result of AGM | RNS |
12.03.2024 14:30 | VARE, NFX, GV2O | UK shareholder meetings calendar - next 7 days | Alliance |
01.03.2024 10:31 | NFX | IN BRIEF: Nuformix announces subscription to raise GBP150,000 | Alliance |
01.03.2024 07:00 | NFX | Subscription to raise £150,000 | RNS |
15.01.2024 11:30 | NFX | Posting of Annual Report and Notice of AGM | RNS |
03.01.2024 10:16 | AZN, NFX | IN BRIEF: Nuformix narrows annual loss as develops drug assets | Alliance |
03.01.2024 07:00 | NFX | Results for the period ended 30 September 2023 | RNS |
18.12.2023 07:00 | NFX | NXP001 Update | RNS |
23.10.2023 12:38 | NFX | Nuformix gets patent in Japan for pulmonary fibrosis treatment NXP002 | Alliance |
23.10.2023 07:00 | NFX | Notice of Allowance of NXP002 Patent in Japan | RNS |
18.09.2023 10:20 | NFX | IN BRIEF: Nuformix to receive milestone payments from Oxilio pact | Alliance |
18.09.2023 07:00 | NFX | NXP001 Update | RNS |
24.08.2023 13:22 | NFX | Result of Annual General Meeting | RNS |
17.08.2023 15:43 | OIG, NFX, CYAN | UK shareholder meetings calendar - next 7 days | Alliance |
31.07.2023 14:00 | NFX | Notice of AGM | RNS |
26.07.2023 14:55 | NFX | Holding(s) in Company | RNS |
02.06.2023 07:00 | NFX | Investor Online Q&A | Reach |
25.05.2023 07:00 | NFX | Change of Auditor | RNS |
22.05.2023 12:45 | NFX | Nuformix loss narrows; near-term goal to focus on NXP002 asset | Alliance |
22.05.2023 07:00 | NFX | Unaudited Interim Report | RNS |
18.05.2023 14:31 | ARV, STB, CIC | TRADING UPDATES: Nuformix says NXP002 shows anti-inflammatory effect | Alliance |
18.05.2023 07:00 | NFX | NXP002 Inflammation and Duration of Action Update | RNS |
26.04.2023 10:55 | NFX | Holding(s) in Company | RNS |
17.04.2023 12:14 | NFX | Nuformix raises GBP70,000 to fund NXP002 programme | Alliance |
17.04.2023 07:00 | NFX | Subscription to raise £70,000 & issue of Warrants | RNS |
27.03.2023 18:42 | NFX, TSTL, AGY | TRADING UPDATES: Sabien works with Empiric; Coro sells in Italy | Alliance |
27.03.2023 07:00 | NFX | NXP002 Update | RNS |
13.03.2023 07:00 | NFX | Change of Accounting Reference Date | RNS |
15.02.2023 12:12 | NFX | Nuformix progresses NXP002 trial after acquiring human tissue | Alliance |
15.02.2023 07:00 | NFX | NXP002 Update | Reach |
03.01.2023 13:37 | NFX | Holding(s) in Company | RNS |
20.12.2022 13:00 | NFX | EQS-News: Nuformix hoping to 'initiate discussions with major pharma' in 2023 | EQS |
20.12.2022 07:00 | NFX | NXP004 Update | RNS |
13.12.2022 14:54 | NFX | Nuformix interim loss virtually flat as continues work on drugs | Alliance |
13.12.2022 07:00 | NFX | Half-year Report | RNS |
05.12.2022 07:00 | NFX | Resignation of Auditor | RNS |
16.11.2022 08:50 | NFX | Holding(s) in Company | RNS |
04.11.2022 07:00 | NFX | Investor Webinar | Reach |
23.09.2022 21:02 | HBR, RKH, NMT | TRADING UPDATES: Neometals swings to loss; Funding Circle strikes deal | Alliance |
23.09.2022 07:00 | NFX | NXP002 Update | RNS |
25.08.2022 14:39 | NFX | Result of AGM | RNS |
19.08.2022 08:57 | NFX | Holding(s) in Company | RNS |
18.08.2022 16:01 | NFX, NWG, MCB | UK shareholder meetings calendar - next 7 days | Alliance |
10.08.2022 11:14 | NFX | IN BRIEF: Nuformix shares rise on tolerability studies completion | Alliance |
10.08.2022 07:00 | NFX | NXP002 Completion of Tolerability Studies | RNS |
01.08.2022 12:13 | NFX | Posting of Annual Report and Notice of AGM | RNS |
28.07.2022 16:14 | NFX, CHRT, CPI | EXECUTIVE CHANGES: Cohort co-founder out; Nuformix co-founder back | Alliance |
28.07.2022 15:01 | NFX, ATST | EARNINGS UPDATES: Alliance Trust beats benchmark and ups dividend | Alliance |
28.07.2022 07:01 | NFX | Board Changes | RNS |
28.07.2022 07:00 | NFX | Annual Results for the year ended 31 March 2022 | RNS |
05.07.2022 07:00 | NFX | NXP002 data to be presented at 2022 ERS Congress | Reach |
29.06.2022 12:25 | AZN, NFX | IN BRIEF: Nuformix shares rise as progresses with cancer programme | Alliance |
29.06.2022 07:00 | NFX | NXP004 Update | RNS |
27.06.2022 21:51 | SYM, SRES, BELL | TRADING UPDATES: Anglo-Eastern Plantations sees palm oil prices rise | Alliance |
27.06.2022 07:00 | NFX | NXP002 Update | RNS |
20.06.2022 07:00 | NFX | Holding(s) in Company | RNS |
31.05.2022 12:41 | NFX | Nuformix Executive Chair Alastair Riddell resigns after one year | Alliance |
31.05.2022 07:00 | NFX | Directorate Change | RNS |
30.05.2022 11:54 | NFX | IN BRIEF: Nuformix shares plunge on inconsistent repeat study results | Alliance |
30.05.2022 11:13 | NFX, SFOR, FOXT | SMALL-CAP WINNERS & LOSERS: Foxtons finds new CEO; S4 revenue surges | Alliance |
30.05.2022 07:00 | NFX | Corporate Update | RNS |
12.04.2022 07:00 | NFX | Second tranche of Lanstead subscription shares | RNS |
11.04.2022 15:54 | NFX | Holding(s) in Company | RNS |
08.04.2022 11:21 | NFX | Holding(s) in Company | RNS |
07.04.2022 15:44 | NFX | Holding(s) in Company | RNS |
05.04.2022 18:07 | NFX | Holding(s) in Company | RNS |
28.03.2022 20:18 | NFX | IN BRIEF: Nuformix NXP004 patent application reaches publication phase | Alliance |
28.03.2022 07:00 | NFX | NXP004 Patent | RNS |
02.03.2022 07:00 | NFX | Appointment of Dr Dan Gooding as Consultant | Reach |
01.03.2022 07:00 | NFX | Change of Auditor | RNS |